|
Tue, 03/24/2020 - 01:20 |
Celyad Oncology Appoints Seasoned Industry Executives to Board of Directors |
Celyad |
|
Fri, 03/20/2020 - 17:51 |
Atnahs acquires rights to established brand in Womens Health treatment |
Triton |
|
Tue, 03/17/2020 - 02:12 |
Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer |
AstraZeneca |
|
Thu, 03/12/2020 - 07:37 |
Update on Phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer |
AstraZeneca |
|
Fri, 03/06/2020 - 05:43 |
Update on Phase III DANUBE trial for Imfinzi and tremelimumab in unresectable, Stage IV bladder cancer |
AstraZeneca |
|
Mon, 03/02/2020 - 05:45 |
AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines |
AstraZeneca |
|
Tue, 02/25/2020 - 17:57 |
AstraZeneca divests global rights to Movantik |
AstraZeneca |
|
Mon, 02/24/2020 - 02:10 |
Interim Report and Half-Year Financial Results |
Starpharma |
|
Mon, 02/10/2020 - 21:09 |
Starpharma receives US$3M milestone from AstraZeneca |
Starpharma |
|
Mon, 01/27/2020 - 10:12 |
AstraZeneca divests rights to established hypertension medicines |
AstraZeneca |
|
Mon, 01/27/2020 - 09:38 |
AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan |
AstraZeneca |
|
Tue, 01/21/2020 - 19:08 |
Syngenta Invests in SciFinder from CAS to Enhance Research Efficiency and Bring Sustainable Agricultural Solutions to Market Faster |
Chemical Abstra... |
|
Mon, 01/06/2020 - 05:12 |
Lokelma approved in China for the treatment of adult patients with hyperkalaemia |
AstraZeneca |
|
Mon, 01/06/2020 - 03:28 |
Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction |
AstraZeneca |
|
Fri, 12/27/2019 - 18:14 |
AstraZenecas Mene Pangalos awarded knighthood in the New Year 2020 Honours List |
AstraZeneca |
|
Fri, 12/20/2019 - 03:49 |
AstraZeneca divests rights to Arimidex and Casodex in Europe and certain additional countries |
AstraZeneca |
|
Mon, 12/16/2019 - 00:05 |
Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed |
AstraZeneca |
|
Thu, 12/12/2019 - 08:09 |
Breast Cancer Preventive Effects of Anastrozole Persist Long After Stopping Treatment |
American Associ... |
|
Thu, 12/12/2019 - 00:44 |
Imfinzi approved in China for the treatment of unresectable, Stage III non-small cell lung cancer based on the Phase III PACIFIC trial |
AstraZeneca |
|
Tue, 12/10/2019 - 19:17 |
Novartis Kisqali data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3 |
Novartis |
|
Tue, 12/03/2019 - 07:27 |
AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada |
AstraZeneca |
|
Fri, 11/29/2019 - 08:58 |
Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer |
AstraZeneca |
|
Thu, 11/21/2019 - 06:26 |
Harvard Business Review names Pascal Soriot among Best Performing Top 100 CEOs in the World 2019 |
AstraZeneca |
|
Thu, 11/14/2019 - 09:08 |
US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review |
Merck |
|
Thu, 11/14/2019 - 03:51 |
US FDA accepts regulatory submission for selumetinib in neurofibromatosis type 1 and grants Priority Review |
AstraZeneca |
